About the company
Inyx, Inc., through its wholly-owned subsidiaries, operates as a specialty pharmaceutical company in the United States, Canada, and Europe. It develops and manufactures prescription and over-the-counter pharmaceutical products. The company manufactures hydrocarbon aerosols, a delivery system for dermatological and topical drug applications; metered dose inhalers that are used for respiratory conditions; dry powdered inhalers used for respiratory ailments; metered dose nasal and throat pumps, and sprays; and sterile salines and injectables. It focuses on research and development activities on inhalation-therapy drug delivery devices and inhalation methods, and generic prescription, and over-the-counter aerosol pharmaceutical products for respiratory, allergy, dermatological, and topical and cardiovascular applications. The company's proprietary products under development include generic versions of nonchlorofluorocarbon or hydrofluoroalkane single molecule and combination drug respiratory inhalants, nonCFC propelled oral sprays for cardiovascular ailments, wound irrigation, and cleansing sprays that utilize novel barrier technologies, and anti-inflammatory nasal pumps. It also provides specialty pharmaceutical development and manufacturing consulting services to the international healthcare market. The company was incorporated in 2000 and is based in New York, New York.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Exchange
- OTCCE
Listing on recordSecurity status from the latest source received, not a guarantee of tradability.
Market information source · Oct 5, 2026
Former names
Periods recorded in the consulted sources. These do not certify the legal dates of name changes.
- DOBLIQUE INCApr 25, 2002 / May 14, 2003
SEC company identity · Oct 5, 2026